| Heart Failure (HF) |
1 |
1 |
| Heart |
0 |
0.81 |
| Cardiomyopathy |
0 |
0.64 |
| Hypertension |
0 |
0.57 |
| Cardiovascular Imaging |
0 |
0.55 |
| Europe |
0 |
0.32 |
| Clinical Guidelines |
0 |
0.24 |
| Quality of Life |
0 |
0.99 |
| Artery |
0 |
0.16 |
| Ejection Fraction |
0 |
0.16 |
| Hospital |
0 |
0.16 |
| Kansas |
0 |
0.16 |
| Patient Safety |
0 |
0.14 |
| Adverse Effects |
0 |
0.08 |
| B-Type Natriuretic Peptide |
0 |
0.08 |
| Board Certification |
0 |
0.08 |
| Clinical Research |
0 |
0.08 |
| Data Collection |
0 |
0.08 |
| Diuretics |
0 |
0.08 |
| Grant |
0 |
0.08 |
| New York |
0 |
0.08 |
| Pandemic |
0 |
0.08 |
| Patient Assessment |
0 |
0.08 |
| Transplant Evaluation |
0 |
0.08 |
| Travel Medicine |
0 |
0.08 |
| COVID-19 |
0 |
0.07 |
| Healthcare and Medical Technology |
0 |
0.07 |
| Myocardial Infarction (MI) |
0 |
0.07 |